Abstract
CytoGam is a hyperimmune globulin created specifically for prophylactic use when a cytomegalovirus seronegative patient receives an organ from a seropositive donor. CytoGam is derived from human pooled plasma rich with cytomegalovirus antibodies, immunoglobulin G, and trace amounts of immunoglobulin A and immunoglobulin M. Clinical studies show a marked decrease in the development of cytomegalovirus when transplant recipients are treated with CytoGam. CytoGam also has undergone trial testing for use in decreasing the instance of cytomegalovirus in patients with human immune deficiency virus (HIV). CytoGam therapy may continue for several months, making home intravenous care essential.